Obesity

Metabolic Diseases
176
Pipeline Programs
30
Companies
50
Clinical Trials
24 recruiting
19
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
51
2
32
1
51
39
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
57100%
+ 174 programs with unclassified modality

On Market (19)

Approved therapies currently available

Rhythm Pharmaceuticals
IMCIVREEApproved
setmelanotide
Rhythm Pharmaceuticals
Melanocortin 4 Receptor Agonist [EPC]subcutaneous2020
U
LIRAGLUTIDEApproved
liraglutide
Unknown Company
GLP-1 Receptor Agonist [EPC]subcutaneous2025
Abbott
MERIDIAApproved
sibutramine hydrochloride
Abbott
oral1997
Eli Lilly and Company
MOUNJAROApproved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2022
Eli Lilly and Company
MOUNJARO (AUTOINJECTOR)Approved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2022
Eli Lilly and Company
MOUNJARO KWIKPENApproved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2022
Novo Nordisk
OZEMPICApproved
semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2017
U
QUDEXY XRApproved
topiramate
Unknown Company
oral2014
Novo Nordisk
RYBELSUSApproved
semaglutide
Novo Nordisk
oral2020
Novo Nordisk
SAXENDAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2014
U
SIVEXTROApproved
tedizolid phosphate
Unknown Company
oral2014
J&
TOPAMAXApproved
topiramate
Johnson & Johnson
oral1996
J&
TOPAMAX SPRINKLEApproved
topiramate
Johnson & Johnson
oral1998
U
TOPIRAMATEApproved
topiramate
Unknown Company
oral2023
Novo Nordisk
VICTOZAApproved
liraglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]subcutaneous2010
Novo Nordisk
WEGOVYApproved
semaglutide
Novo Nordisk
GLP-1 Receptor Agonist [EPC]oral2025
Eli Lilly and Company
ZEPBOUNDApproved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2023
Eli Lilly and Company
ZEPBOUND (AUTOINJECTOR)Approved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2023
Eli Lilly and Company
ZEPBOUND KWIKPENApproved
tirzepatide
Eli Lilly and Company
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]subcutaneous2023

Competitive Landscape

50 companies ranked by most advanced pipeline stage

Novo Nordisk
86 programs
21
6
21
6
Behavioral TreatmentPhase 41 trial
SaxendaPhase 41 trial
SaxendaPhase 41 trial
SemaglutidePhase 4Peptide1 trial
SemaglutidePhase 4Peptide1 trial
+81 more programs
Active Trials
NCT06855563Enrolling By Invitation36,000Est. Dec 2027
NCT00908973Completed46Est. Dec 2011
NCT06752967Recruiting45Est. Dec 2026
+82 more trials
Pfizer
13 programs
6
3
1
1
Caltrate® 600 + DPhase 41 trial
CP-945,598Phase 31 trial
CP-741,952Phase 21 trial
MET097Phase 21 trial
PF-07976016Phase 21 trial
+8 more programs
Active Trials
NCT01243138Completed4,386Est. Apr 2012
NCT00746460Completed50Est. Oct 2009
NCT00376285Withdrawn0
+12 more trials
E
13 programs
3
2
4
2
ZonegranPhase 41 trial
lorcaserin hydrochloride XRPhase 41 trial
Lorcaserin 10 mg BIDPhase 31 trial
Lorcaserin 10 mg once dailyPhase 31 trial
Lorcaserin 10 mg once dailyPhase 31 trial
+8 more programs
Active Trials
NCT03552107Completed157Est. Apr 2019
NCT02388568Completed137Est. Jun 2017
NCT00828724Completed24Est. Dec 2008
+10 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
11 programs
3
1
6
1
TirzepatidePhase 4Peptide1 trial
EloralintidePhase 3Peptide5 trials
OrforglipronPhase 31 trial
OrforglipronPhase 35 trials
RetatrutidePhase 3Peptide1 trial
+6 more programs
Active Trials
NCT06557356Completed132Est. Dec 2025
NCT06297616Completed128Est. Nov 2025
NCT06824051Completed120Est. Jan 2026
+16 more trials
M&
Merck & Co.RAHWAY, NJ
10 programs
6
2
2
Imipenem/Cilastatin/Relebactam 1.25gPhase 41 trial
Tedizolid phosphatePhase 41 trial
MK0557Phase 31 trial
MK0557Phase 31 trial
MK0364Phase 21 trial
+5 more programs
Active Trials
NCT00109148Completed500Est. Feb 2005
NCT00482638CompletedEst. Oct 2004
NCT00482196Completed173Est. Mar 2006
+7 more trials
Abbott
AbbottABBOTT PARK, IL
4 programs
1
1
Sibutramine hydrochloridePhase 31 trial
Role of Nutrition and Maternal Genetics on the Programming of Development of Fetal Adipose TissueN/A1 trial
State of Obesity Care in Canada Evaluation RegistryN/A1 trial
protein and meal frequencyN/A1 trial
Active Trials
NCT01634464Unknown300Est. Jun 2013
NCT00328081Terminated1,906Est. Aug 2007
NCT01749449Completed30Est. Jan 2007
+1 more trials
Sanofi
4 programs
3
1
Enoxaparin 0.5 mg/kg once dailyPhase 41 trial
RimonabantPhase 31 trial
rimonabantPhase 31 trial
rimonabantPhase 31 trial
Active Trials
NCT00478595Terminated458Est. Feb 2009
NCT00386061Completed1,507Est. Jun 2004
NCT00412698Terminated645Est. Jan 2009
+1 more trials
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
3 programs
1
1
topiramatePhase 31 trial
Packaging and identification of sourceN/A1 trial
Real-Time Incentives GroupN/A1 trial
Active Trials
NCT00185536Completed100
NCT04235413Completed244Est. Nov 2022
NCT00231634Terminated31Est. Nov 2002
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
3 programs
3
ContravePhase 41 trial
Contrave 8Mg-90Mg Extended-Release TabletPhase 41 trial
Contrave 8Mg-90Mg Extended-Release TabletPhase 41 trial
Active Trials
NCT06809166RecruitingEst. Jul 2026
NCT04589130UnknownEst. Dec 2023
NCT04587843UnknownEst. Dec 2023
Novartis
NovartisBASEL, Switzerland
2 programs
1
1
Sandostatin LARPhase 41 trial
LLF580Phase 11 trial
Active Trials
NCT03466203Completed61Est. Nov 2019
NCT00076362Completed60
Rhythm Pharmaceuticals
1 program
1
1
SetmelanotidePhase 3Peptide1 trial
Active Trials
NCT05093634Active Not Recruiting296Est. Dec 2026
Takeda
1 program
1
Candesartan and HydrochlorothiazidePhase 41 trial
Active Trials
NCT00775814Completed188Est. Sep 2008
Astellas
AstellasChina - Shenyang
1 program
1
MicafunginPhase 41 trial
Active Trials
NCT01090141Completed36Est. Jun 2010
Alvogen
1 program
1
Qsymia 3.75Mg-23Mg Extended Release CapsulePhase 41 trial
Active Trials
NCT05378503Completed232Est. Oct 2023
Boehringer Ingelheim
5
3
6
SurvodutidePhase 3Peptide1 trial
SurvodutidePhase 3Peptide1 trial
SurvodutidePhase 3Peptide1 trial
survodutidePhase 3Peptide1 trial
survodutidePhase 3Peptide1 trial
+10 more programs
Active Trials
NCT04447261Completed87Est. Apr 2021
NCT03591718Completed131Est. Apr 2020
NCT05202353Recruiting30Est. Nov 2026
+11 more trials
Amgen
5 programs
1
2
Maridebart CafraglutidePhase 3Peptide1 trial
Maridebart cafraglutidePhase 3Peptide1 trial
Maridebart CafraglutidePhase 2Peptide1 trial
TAP® Micro Select DeviceN/A1 trial
caffeine and ephedrineN/A1 trial
Active Trials
NCT06761703Completed200Est. Jan 2025
NCT01710722Completed45Est. Feb 2002
NCT05669599Completed592Est. Dec 2025
+2 more trials
Kailera Therapeutics
1
2
KAI-9531Phase 31 trial
KAI-9531Phase 32 trials
KAI-7535Phase 11 trial
Active Trials
NCT07294898Completed18Est. Jan 2026
NCT07284979Recruiting1,200Est. Apr 2028
NCT07458269Not Yet Recruiting250Est. Jun 2027
+1 more trials
CT
1
TQF3510Phase 31 trial
Active Trials
NCT06738979Not Yet RecruitingEst. Aug 2026
OD
1 program
1
topiramatePhase 2/3
Kallyope
KallyopeNY - New York
4 programs
3
1
K-757 120 mg BID and K-833 100 mg BIDPhase 21 trial
K-757Phase 11 trial
K-757 and K-833Phase 11 trial
K-757 and K-833 QDPhase 11 trial
Active Trials
NCT05900531CompletedEst. May 2023
NCT05890950CompletedEst. Jul 2023
NCT06305351CompletedEst. Jun 2024
+1 more trials
Sciwind Biosciences
Sciwind BiosciencesChina - Hangzhou
3 programs
1
2
XW003Phase 21 trial
XW003 injectionPhase 21 trial
T2026Phase 11 trial
Active Trials
NCT05184322CompletedEst. Mar 2025
NCT05111912CompletedEst. Dec 2022
NCT07073417RecruitingEst. Aug 2027
Ionis Pharmaceuticals
1 program
1
ISIS-FGFR4RXPhase 21 trial
Active Trials
NCT02476019Completed13Est. Sep 2016
MindRank
MindRankChina - Shanghai
1 program
1
MDR-001Phase 21 trial
Active Trials
NCT06606483Not Yet RecruitingEst. Sep 2025
NodThera
NodTheraPA - Philadelphia
1 program
1
NT-0796Phase 21 trial
Active Trials
NCT07220629Active Not Recruiting80Est. Jun 2026
Skye Bioscience
Skye BioscienceSAN DIEGO, CA
1 program
1
Nimacimab injectionPhase 21 trial
Active Trials
NCT06577090Active Not Recruiting136Est. Feb 2027
Biohaven
BiohavenNEW HAVEN, CT
1 program
1
Taldefgrobep AlfaPhase 21 trial
Active Trials
NCT07281495RecruitingEst. Sep 2026
VP
1
TradipitantPhase 21 trial
Active Trials
NCT06804603Completed124Est. Oct 2025
Palatin Technologies
1
bremelanotidePhase 2Peptide1 trial
Active Trials
NCT06565611Active Not RecruitingEst. Mar 2025
Arrowhead Pharmaceuticals
2
ARO-ALK7Phase 1/21 trial
ARO-INHBEPhase 1/21 trial
Active Trials
NCT06937203Recruiting126Est. Jul 2026
NCT06700538Recruiting120Est. May 2026
AbbVie
1 program
1
ABBV-295Phase 12 trials
Active Trials
NCT07414784Recruiting20Est. Jul 2026
NCT07291232Recruiting96Est. Oct 2026

+20 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Eli Lilly and CompanyTirzepatide
Novo NordiskSemaglutide
Bausch HealthContrave
Novo NordiskSemaglutide
Merck & Co.Imipenem/Cilastatin/Relebactam 1.25g
Novo NordiskBehavioral Treatment
AlvogenQsymia 3.75Mg-23Mg Extended Release Capsule
Bausch HealthContrave 8Mg-90Mg Extended-Release Tablet
Bausch HealthContrave 8Mg-90Mg Extended-Release Tablet
Novo NordiskWeight Management Program
Novo NordiskSaxenda
Eisailorcaserin hydrochloride XR
Novo NordiskSaxenda
Merck & Co.Tedizolid phosphate
AstellasMicafungin

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 38,691 patients across 50 trials

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

Start: Nov 2025Est. completion: Jul 20323,000 patients
Phase 4Recruiting

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

Start: Sep 2024Est. completion: Nov 2031500 patients
Phase 4Active Not Recruiting

Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity

Start: Jul 2024Est. completion: Jul 2026
Phase 4Recruiting

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Start: Jan 2023Est. completion: Nov 2024500 patients
Phase 4Completed
NCT05146154Merck & Co.Imipenem/Cilastatin/Relebactam 1.25g

Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients

Start: Jan 2023Est. completion: Jan 20240
Phase 4Withdrawn
NCT05548647Novo NordiskBehavioral Treatment

Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects

Start: Jul 2022Est. completion: May 2025120 patients
Phase 4Completed
NCT05378503AlvogenQsymia 3.75Mg-23Mg Extended Release Capsule

Phase IV Study of Qsymia in Obese Patients

Start: Sep 2021Est. completion: Oct 2023232 patients
Phase 4Completed
NCT04587843Bausch HealthContrave 8Mg-90Mg Extended-Release Tablet

A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery

Start: Apr 2021Est. completion: Dec 2023
Phase 4Unknown
NCT04589130Bausch HealthContrave 8Mg-90Mg Extended-Release Tablet

Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.

Start: Feb 2021Est. completion: Dec 2023
Phase 4Unknown
NCT03799198Novo NordiskWeight Management Program

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

Start: Jan 2019Est. completion: May 2020200 patients
Phase 4Completed

Saxenda in Obesity Services (STRIVE Study)

Start: Nov 2017Est. completion: Feb 2022392 patients
Phase 4Completed
NCT03338296Eisailorcaserin hydrochloride XR

Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

Start: Sep 2017Est. completion: Apr 2020278 patients
Phase 4Terminated

Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery

Start: May 2017Est. completion: Mar 2021132 patients
Phase 4Completed
NCT02342418Merck & Co.Tedizolid phosphate

Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults

Start: Mar 2015Est. completion: Dec 201519 patients
Phase 4Completed

Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers

Start: Nov 2009Est. completion: Jun 201036 patients
Phase 4Completed
NCT00585182SanofiEnoxaparin 0.5 mg/kg once daily

Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT

Start: Jan 2007Est. completion: Apr 200828 patients
Phase 4Completed
NCT00775814TakedaCandesartan and Hydrochlorothiazide

Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.

Start: Oct 2006Est. completion: Sep 2008188 patients
Phase 4Completed
NCT00076362NovartisSandostatin LAR

Pediatric Hypothalamic Obesity

Start: Mar 200460 patients
Phase 4Completed

Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial

Start: May 2003Est. completion: Mar 200620 patients
Phase 4Completed
NCT00353054PfizerCaltrate® 600 + D

Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.

Start: Jan 2003Est. completion: Jul 200580 patients
Phase 4Completed

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Start: May 2026Est. completion: Jan 20291,000 patients
Phase 3Not Yet Recruiting

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

Start: Feb 2026Est. completion: Aug 20291,150 patients
Phase 3Recruiting

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Start: Feb 2026Est. completion: Jul 2028900 patients
Phase 3Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Start: Feb 2026Est. completion: Apr 2028800 patients
Phase 3Recruiting

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Start: Feb 2026Est. completion: May 2028900 patients
Phase 3Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Start: Feb 2026Est. completion: Jul 20301,980 patients
Phase 3Recruiting

Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Start: Dec 2025Est. completion: Apr 20281,200 patients
Phase 3Recruiting
NCT07225686AmgenMaridebart cafraglutide

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Start: Dec 2025Est. completion: Sep 2028250 patients
Phase 3Recruiting

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Start: Dec 2025Est. completion: Mar 20281,800 patients
Phase 3Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Start: Dec 2025Est. completion: Feb 20281,035 patients
Phase 3Recruiting

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Start: Dec 2025Est. completion: Aug 20317,140 patients
Phase 3Recruiting

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Start: Nov 2025Est. completion: Jun 2027300 patients
Phase 3Active Not Recruiting

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Start: Oct 2025Est. completion: Jun 20281,205 patients
Phase 3Recruiting

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Start: Sep 2025Est. completion: Mar 20281,000 patients
Phase 3Recruiting

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

Start: Sep 2025Est. completion: May 2028800 patients
Phase 3Recruiting

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

Start: Jun 2025Est. completion: Oct 2028609 patients
Phase 3Active Not Recruiting

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Start: May 2025Est. completion: Sep 2027586 patients
Phase 3Recruiting

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Start: May 2025Est. completion: Aug 2027600 patients
Phase 3Recruiting

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Start: May 2025Est. completion: Aug 20271,200 patients
Phase 3Recruiting

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Start: May 2025Est. completion: Aug 2027600 patients
Phase 3Recruiting

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Start: Apr 2025Est. completion: Sep 2027487 patients
Phase 3Recruiting

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

Start: Apr 2025Est. completion: Sep 2027974 patients
Phase 3Recruiting

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

Start: Apr 2025Est. completion: Sep 2027487 patients
Phase 3Recruiting
NCT06858839AmgenMaridebart Cafraglutide

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Start: Mar 2025Est. completion: Apr 20273,853 patients
Phase 3Active Not Recruiting

A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

Start: Mar 2025Est. completion: Aug 2026
Phase 3Not Yet Recruiting

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

Start: Feb 2025Est. completion: Oct 2028400 patients
Phase 3Active Not Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Start: Nov 2024Est. completion: Mar 2027125 patients
Phase 3Recruiting

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Start: Nov 2024Est. completion: Mar 2027125 patients
Phase 3Recruiting

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Start: Nov 2024Est. completion: Dec 2026800 patients
Phase 3Active Not Recruiting

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Start: Oct 2024Est. completion: Jan 2027600 patients
Phase 3Active Not Recruiting

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

51 late-stage (Phase 3) programs — potential near-term approvals
24 actively recruiting trials targeting 38,691 patients
30 companies competing in this space